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Pharmacotherapy of Treatment-resistant Combat-related Posttraumatic 
Stress Disorder with Psychotic Features
Aim To assess retrospectively the clinical effects of typical (flu-
phenazine) or atypical (olanzapine, risperidone, quetiapine) 
antipsychotics in three open clinical trials in male Croatian 
war veterans with chronic combat-related posttraumatic stress 
disorder (PTSD) with psychotic features, resistant to previous 
antidepressant treatment.
Methods Inpatients with combat-related PTSD were treated 
for 6 weeks with fluphenazine (n = 27), olanzapine (n = 28), 
risperidone (n = 26), or quetiapine (n = 53) as a monotherapy. 
Treatment response was assessed by the reduction in total and 
subscales scores in the clinical scales measuring PTSD (PTSD 
interview and Clinician-administered PTSD Scale) and psy-
chotic symptoms (Positive and Negative Syndrome Scale).
Results After 6 weeks of treatment, monotherapy with fluphen-
azine, olanzapine, risperidone, or quetiapine in patients with 
PTSD significantly decreased the scores listed in trauma reex-
periencing, avoidance, and hyperarousal subscales in the clinical 
scales measuring PTSD, and total and subscales scores listed in 
positive, negative, general psychopathology, and supplementary 
items of the Positive and Negative Syndrome Scale subscales, 
respectively (P<0.001).
Conclusion PTSD and psychotic symptoms were significantly 
reduced after monotherapy with typical or atypical antipsychot-
ics. As psychotic symptoms commonly occur in combat-related 
PTSD, the use of antipsychotic medication seems to offer an-
other approach to treat a psychotic subtype of combat-related 
PTSD resistant to previous antidepressant treatment.
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In a world in which terrorism and conflicts are 
constant threats, and these threats are becoming 
global, posttraumatic stress disorder (PTSD) is 
a serious and global illness. According to the cri-
teria from the 4th edition of Diagnostic and Sta-
tistical Manual of Mental Disorders (DSM-IV) 
(1), exposure to a life-threatening or horrifying 
event, such as combat trauma, rape, sexual mo-
lestation, abuse, child maltreatment, natural di-
sasters, motor vehicle accidents, violent crimes, 
hostage situations, or terrorism, can lead to the 
development of PTSD (1,2). The disorder may 
also be precipitated if a person experienced, saw, 
or learned of an event or events that involved ac-
tual or threatened death, serious injury, or viola-
tion of the body of self or others (3,4). In such 
an event a person’s response can involve intense 
fear, helplessness, or horror (3,4). However, not 
all persons who are exposed to a traumatic event 
will develop PTSD. Although the stress reaction 
is a normal response to an abnormal situation, 
some extremely stressful situations will in some 
individuals overwhelm their ability to cope with 
stress (5).
PTSD is a chronic psychiatric illness. The es-
sential features of PTSD are the development of 
three characteristic symptom clusters in the af-
termath of a traumatic event: re-experiencing 
the trauma, avoidance and numbing, and hyper-
arousal (1,6). The core PTSD symptoms in the 
re-experiencing cluster are intrusive memories, 
images, or perceptions; recurring nightmares; 
intrusive daydreams or flashbacks; exaggerated 
emotional and physical reactions; and dissocia-
tive experiences (1,6,7). These symptoms intensi-
fy or re-occur upon exposure to reminders of the 
trauma, and various visual, auditory, or olfactory 
cues might trigger traumatic memories (3,4). The 
avoidance and numbing cluster of symptoms in-
cludes efforts to avoid thoughts, feelings, activi-
ties, or situations associated with the trauma; 
feelings of detachment or alienation; inability 
to have loving feelings; restricted range of affect; 
loss of interest; and avoidance of activity. The hy-
perarousal cluster includes exaggerated startle re-
sponse, hyper-vigilance, insomnia and other sleep 
disturbances, difficulties in concentrating, and ir-
ritability or outbursts of anger. PTSD criteria in-
clude functional impairment, which can be seen 
in occupational instability, marital problems, dis-
cord with family and friends, and difficulties in 
parenting (3,4,8). In addition to this social and 
occupational dysfunction, PTSD is often accom-
panied by substance abuse (9) and by various co-
morbid diagnoses, such as major depression (10), 
other anxiety disorders, somatization, personality 
disorders, dissociative disorders (7,11), and fre-
quently with suicidal behavior (12). Combat ex-
posure can precipitate a more severe clinical pic-
ture of PTSD, which may be complicated with 
psychotic features and resistance to treatment. 
War veterans with PTSD have a high risk of sui-
cide, and military experience, guilt about combat 
actions, survivor guilt, depression, anxiety, and 
severe PTSD are significantly associated with sui-
cide attempts (12).
The pharmacotherapy treatment of PTSD 
includes the use of antidepressants, such as selec-
tive serotonin reuptake inhibitors (fluvoxamine, 
fluoxetine, sertraline, or paroxetine) as the first 
choice of treatment, tricyclic antidepressants (de-
sipramine, amitriptyline, imipramine), mono-
amine oxidase inhibitors (phenelzine, brofaro-
mine), buspirone and other antianxiety agents; 
benzodiazepines (alprazolam), and mood stabi-
lizers (lithium) (13-16). Although the pharmaco-
therapy of PTSD starts with antidepressants, in 
treatment-refractory patients a new pharmaco-
logical approach is required to obtain a response. 
In treatment-resistant patients, pharmacothera-
py strategies reported to be effective include anti-
convulsants, such as carbamazepine, gabapentine, 
topiramate, tiagabine, divalproex, lamotrigine 
(14,17); anti-adrenergic agents, such as clonidine 
(although presynaptic α2-adrenoceptor agonist, 
clonidine blocks central noradrenergic outflow 
from the locus ceruleus), propranolol, and prazo-
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sin (13,14), opiate antagonists (13), and neuro-
leptics and antipsychotics (14,17,18).
Combat exposure frequently induces PTSD, 
and combat-related PTSD might progress to a 
severe form of PTSD, which is often refracto-
ry to treatment (19-21). Combat-related PTSD 
is frequently associated with comorbid psychot-
ic features (11,14,17,19-21), while psychotic fea-
tures add to the severity of symptoms in combat-
related PTSD patients (19,22-24). These cases of 
a more severe subtype of PTSD, complicated with 
psychotic symptoms, require the use of neurolep-
tics or atypical antipsychotic drugs (14,17,25-27).
After the war in Croatia (1991-1995), an es-
timated million people were exposed to war trau-
ma and about 10 000 of the Homeland War vet-
erans (15% prevalence) have developed PTSD, 
with an alarmingly high suicide rate (28). The 
war in Croatia brought tremendous suffering, 
not only to combat-exposed veterans and pris-
oners of war (29), but also to different groups of 
traumatized civilians in the combat zones, dis-
placed persons and refugees, victims of terrorist 
attacks, civilian relatives of traumatized war vet-
erans and terrorist attacks victims, and trauma-
tized children and adolescents (30). Among Cro-
atian war veterans with combat-related PTSD, 
57-62% of combat soldiers with PTSD met cri-
teria for comorbid diagnoses (8-11), such as al-
cohol abuse, major depressive disorder, anxiety 
disorders, panic disorder and phobia, psychoso-
matic disorder, psychotic disorders, drug abuse, 
and dementia. In addition to different comor-
bid psychiatric disorders, a great proportion of 
war veterans with combat-related PTSD devel-
oped psychotic features (8,11,25,26), which con-
sisted of psychotic depressive and schizophrenia-
like symptoms (suggesting prominent symptoms 
of thought disturbances and psychosis). Psychot-
ic symptoms were accompanied by auditory or 
visual hallucinations and delusional thinking in 
over two-thirds of patients (25,26). Delusional 
paranoid symptoms occurred in 32% of patients 
(25,26). The hallucinations were not associated 
exclusively with the traumatic experience, while 
the delusions were generally paranoid or per-
secutory in nature (25,26). Although psychot-
ic PTSD and schizophrenia share some similar 
symptoms, there are clear differences between 
these two entities, since PTSD patients still re-
tain some insight into reality and usually do not 
have complete disturbances of affect (eg, con-
stricted or inappropriate) or thought disorder 
(eg, loose associations or disorganized responses).
This proportion of veterans with combat-re-
lated PTSD refractory to treatment (18-20) and 
with co-occurring psychotic symptoms requires 
additional pharmacological strategies, such as the 
use of neuroleptics (25) or atypical antipsychot-
ics (14,17,26). Studies evaluating the use of an-
tipsychotics in combat-related PTSD with psy-
chotic features are scarce, and antipsychotics 
were frequently added to existing medication in 
the treatment of PTSD.
In this study, we compared retrospectively 
the clinical effects of four antipsychotic drugs – a 
neuroleptic drug (fluphenazine) and three atyp-
ical antipsychotics (olanzapine, risperidone and 
quetiapine) – in treatment-resistant male war 




The study included Caucasian male war veter-
ans from Croatia, aged between 33 and 51 years 
(mean±SD age, 38.0 ± 4.7), who were active sol-
diers in the Croatian armed forces and had on 
average 3.0 ± 1.0 years of continuous combat ex-
perience. The veterans were recruited from the 
Referral Center of the Ministry of Health and 
Social Welfare for the Stress-related Disorders, 
Regional Center for Psychotrauma, Depart-
ment of Psychiatry, Dubrava University Hospi-
tal, from 1998 to 2005. The diagnosis of PTSD 
was made according to the DSM-IV criteria (1) 
by use of a structured clinical interview (31). 
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The screening of the patients included psychiat-
ric, physical, and neurological examinations. The 
study was approved by the Ethics Committee 
of the University Hospital Dubrava. The proce-
dure was fully explained and all patients provid-
ed written informed consent to the treating psy-
chiatrists. Wash-out was 2-4 weeks. During this 
period, patients sporadically used up to 10 mg of 
diazepam.
Inclusion and exclusion criteria
Inclusion criteria. Patients had to be older than 
18 years, meet DSM-IV criteria for chronic 
PTSD, and be able to provide written informed 
consent. Patients had to present a psychotic 
PTSD subtype, with psychotic combat-relat-
ed symptoms, which were secondary to the pri-
mary PTSD, and be refractory to antidepressant 
therapy in the previous 12 months. Refractori-
ness to treatment was observed in patients who 
did not respond well in the previous 12 months 
to treatment with selective serotonin reuptake 
inhibitors, tricyclic antidepressants, other anti-
depressants, sedative hypnotics, or anticonvul-
sants. Patients were considered to be refracto-
ry to treatment if they were treated sequentially 
in two 8-week treatments with different classes 
of antidepressants without a positive clinical re-
sponse (worsening of symptoms, no change, or 
slight improvement). These patients were re-
ferred by their local psychiatrist(s) to the Referral 
Center for the Stress Related Disorders. During 
these 12 months, patients were treated sporadi-
cally or continuously with sedative hypnotics be-
cause of the sleep disturbances and nightmares 
and anticonvulsants in combination with tricy-
clic antidepressants or selective serotonin reup-
take inhibitors or other antidepressants to reduce 
aggressive behavior. The strategy is that if pa-
tients are non-responsive to medication, they are 
referred from different centers and parts of Cro-
atia to the Referral Center for the Stress Related 
Disorders. Before enrollment, the patients had 
been washed out from medication for 4 weeks if 
they had received fluoxetine, and 2 weeks if they 
had received other selective serotonin reuptake 
inhibitors or tricyclic antidepressants or anticon-
vulsants. Therefore, refractoriness to treatment 
was not a single failed trial, and most patients 
had been treated unsuccessfully for a longer pe-
riod of time before they were referred to the Re-
ferral Center for the Stress Related Disorders. In 
addition, patients had to be free of antipsychotic 
drugs for at least one month prior to the entry in 
the study.
Exclusion criteria. Patients were excluded 
from the study if they had positive family history 
of psychosis, history of schizophrenia, schizoaf-
fective or bipolar disorder, lifetime schizophre-
nia, bipolar disorder, or cognitive dysfunction 
due to a medical condition; past thought dis-
order or bizarre behavior; history of alcohol or 
other substance use disorder within 3 months; 
mental retardation; significant risk of violence or 
suicide; serious concomitant medical condition; 
clinically significant abnormalities in electrocar-
diogram or laboratory findings; including posi-
tive urine screen for illicit drugs; history of prior 
treatment with fluphenazine, olanzapine, risper-
idone or quetiapine; concomitant therapy with 
psychotropic medications; need for concurrent 
psychotherapy; and if the psychotic symptoms 
occurred only during a flashback or dissociative 
episode. Psychiatric comorbidity was assessed by 
means of the Mini-International Neuropsychiat-
ric Interview (MINI) (32). In addition, patients 
were excluded if they scored 19 or higher on the 
Hamilton Rating Scale for Depression (33) to 
exclude the comorbidity with major depression 
and to ensure that only patients with PTSD with 
psychotic features were included. However, this 
criterion may bias the sample as so many patients 
with PTSD do have comorbid major depression.
Psychotic symptoms
Psychotic symptoms were associated with the 
traumatic event, ie, they were combat-relat-
ed: scenes of war; faces of dead people; slaugh-
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tered, massacred, and disintegrated bodies; imag-
es of screaming soldiers or enemies trying to kill 
them; sounds of fire, bombing, shell and rocket 
fire; and so on. Psychotic symptoms were defined 
as evidence of hallucinations or delusions dur-
ing the mental status examination, with a score 
of at least 4 (moderate severity) on the 4 critical 
positive items on the Positive and Negative Syn-
drome scale (34) (delusions, conceptual disorga-
nization, hallucinatory behavior, suspiciousness/
persecution), 2 negative items (emotional with-
drawal, and passive/apathetic social withdraw-
al), 8 items out of the general psychopathology 
subscale (guilt feelings, depression, motor retar-
dation, unusual thought content, disorientation, 
disturbance of volition, poor impulse control and 
active social avoidance), and 2 items on the sup-
plementary subscale (anger and affective lability).
Method
We retrospectively analyzed 3 open-labeled 6-
week studies, during which the patients received 
either fluphenazine (27 patients) or olanzap-
ine (28 patients) 5-10 mg/d, or risperidone (26 
patients) 2-4 mg/d, or quetiapine (53 patients) 
25-400 mg/d, as a monotherapy. The necessary 
adjustments of the doses were made, as appropri-
ate, after weekly visits, and clinical response, effi-
cacy, and tolerability of treatment were evaluat-
ed weekly. The only concomitant psychotropic 
medications allowed during the study were zolpi-
dem and biperidone for the side effects.
Outcome measures
The outcome measures used were total and sub-
scale (re-experiencing, avoidance, and hyper-
arousal) scores on the PTSD interview (35) and 
the Clinician-administered PTSD scale (36), 
and total and subscale (positive psychotic symp-
toms, negative symptoms, global psychopatholo-
gy, and supplementary items) scores on the Pos-
itive and Negative Syndrome scale. The scores 
were compared to assess the efficacy of different 
antipsychotic drugs. Since the Clinician-admin-
istered PTSD scale and the PTSD interview are 
both clinical scales measuring PTSD symptoms, 
with similar questions and scores, the data mea-
suring PTSD symptoms were combined. The 
PTSD interview was standardized for the Croa-
tian population (37,38) (psychometric charac-
teristics of the Watson’s PTSD questionnaire 
included internal consistency with α = 0.92 and 
test = retest reliability with r = 0.95). Clinical im-
provement was assessed with the Clinical Global 
Impressions - Severity of Illness scale (39). Safety 
and tolerability assessments were recorded dur-
ing weekly visits by the Patient Global Impres-
sion Improvement scale and the Drug Induced 
Extra-pyramidal Symptoms scale (40).
Statistical analysis
Analyzed data were presented as means with 
standard deviations (mean±SD) and evaluated 
with one-way analysis of variance (ANOVA), 
followed by Tukey’s multiple comparison tests. 
P<0.05 was considered statistically significant. 
Statistical analysis was conducted with SigmaStat 
2.0 and SigmaStat 3.1 (Jandell Scientific Corp., 
San Raphael, CA, USA).
Results
Although analysis of variance showed an over-
all significant effect of age (P = 0.030, ANO-
VA), post-hoc comparison revealed that the age 
of patients did not significantly differ between 
groups treated with fluphenazine (38.1 ± 4.8 
years), olanzapine (37.2 ± 4.5 years), risperidone 
(36.9 ± 4.0 years), or quetiapine (39.9 ± 5.5 years) 
(P = 0.051-0.996, Tukey’s test). There was no sig-
nificant difference in duration of combat expo-
sure between PTSD patients treated with flu-
phenazine (2.9 ± 0.9 years), olanzapine (3.1 ± 0.9 
years), risperidone (3.0 ± 1.0 years) or quetiapine 
(2.9 ± 1.0 years) (P = 0.841, ANOVA).
Before treatment with fluphenazine, olan-
zapine or risperidone, the patient groups did not 
differ in total PTSD symptom scores (P = 0.859-
445
Pivac and Kozarić-Kovačić: Antipsychotics for Treatment-resistant PTSD
1.000, Tukey’s test; Figure 1). The pretreat-
ment scores in war veterans who received que-
tiapine therapy for 6 weeks were significantly 
lower than scores in all other groups of patients 
(P<0.001, Tukey’s test; Figure 1). Six weeks of 
treatment with fluphenazine, olanzapine, risper-
idone or quetiapine significantly reduced  total 
(Figure 1) and subscale PTSD symptom scores 
in trauma reexperiencing (Figure 2), avoidance 
(Figure 3), and hyperarousal (Figure 4) subscales 
(P<0.001 for all, Tukey’s test). The treatment 
with fluphenazine or quetiapine equally lowered 
total PTSD symptom scores by 46% and 41% in 
comparison with the baseline scores, respectively, 
while the treatment with olanzapine or risperi-
done elicited greater reductions of PTSD symp-
toms by 63% and 62% in comparison with the 
baseline scores, respectively (Figure 1). The effects 
of all antipsychotics were comparable on trau-
ma re-experiencing scores (Figure 2). Avoidance 
scores were equivalently reduced after treatment 
with fluphenazine and quetiapine (35% and 37% 
of the baseline scores,  respectively), while treat-
ment with olanzapine or risperidone decreased 
the avoidance scores even more, ie, by 58% and 
59% in comparison with the baseline scores, re-
spectively (Figure 3). A significant reduction by 
70% from the baseline hyperarousal scores was 
achieved after olanzapine or risperidone (Figure 
4). Treatment with fluphenazine induced a sig-
nificant (52%) reduction of the baseline scores, 
while quetiapine treatment decreased the hyper-
arousal scores by 35% (Figure 4).
Treatment with fluphenazine, olanzapine, 
risperidone, or quetiapine for 6 weeks signifi-
cantly decreased total (Figure 5) and subscales 
scores in positive (Figure 6), negative (Figure 7), 
general psychopathology (Figure 8), and supple-
mentary items (Figure 9) of Positive and Nega-
tive Syndrome scale (P<0.001 for all, Tukey’s 
test). This reduction of the baseline scores was of 
the similar magnitude after treatment with olan-
zapine (63%), risperidone (62%), or quetiapine 
(62%). Fluphenazine treatment induced a slight-
Figure 1. Total posttraumatic stress disorder (PTSD) scores 
(mean ± standard deviation) before and after 6 weeks of treatment 
with fluphenazine (open bars), olanzapine (light gray bars), risperi-
done (closed bars), or quetiapine (dark gray bars) in 134 war vete-
rans with PTSD; P<0.001 for each treatment group before vs after 
treatment. *P<0.001 vs the scores before treatment with fluphenazine, 
risperidone, olanzapine (Tukey’s test). †P<0.001 vs the scores after 6 
weeks of treatment with olanzapine or risperidone.
Figure 2. Trauma re-experiencing scores (mean ± standard deviation) 
before and after 6 weeks of treatment with fluphenazine (open bars), 
olanzapine (light gray bars), risperidone (closed bars), or quetiapine 
(dark gray bars) in war veterans with posttraumatic stress disorder. 
P<0.001 for each treatment group before vs after treatment (Tukey’s 
test.
Figure 3. Avoidance scores (mean ± standard deviation) before and 
after 6 weeks of treatment with fluphenazine (open bars), olanzapine 
(light gray bars), risperidone (closed bars), or quetiapine (dark gray 
bars) in war veterans with posttraumatic stress disorder. P<0.001 for 
each treatment group before vs after treatment. *P<0.001 vs the sco-
res after 6 weeks of treatment with risperidone, olanzapine or quetia-
pine (Tukey’s test). †P<0.001 vs the scores after 6 weeks of treatment 
with risperidone, or olanzapine (Tukey’s test).
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Figure 4. Hyperarousal scores (mean ± standard deviation) before 
and after 6 weeks of treatment with fluphenazine (open bars), olan-
zapine (light gray bars), risperidone (closed bars), or quetiapine (dark 
gray bars) in war veterans with psychotic combat-related posttrauma-
tic stress disorder. P<0.001 for each treatment group before vs after 
treatment. *P<0.001 vs the scores after 6 weeks of treatment with 
risperidone or olanzapine (Tukey’s test).
Figure 5. Positive and Negative Syndrome Scale total scores 
(mean ± standard deviation) before and after 6 weeks of treatment with 
fluphenazine (open bars), olanzapine (light gray bars), risperidone 
(closed bars), or quetiapine (dark gray bars) in war veterans with psyc-
hotic combat-related posttraumatic stress disorder. P<0.001 for each 
treatment group before vs after treatment. *P<0.001 vs the scores af-
ter 6 weeks of treatment with risperidone, olanzapine or quetiapine 
(Tukey’s test).
Figure 6. Positive and Negative Syndrome Scale positive scores 
(mean ± standard deviation) before and after 6 weeks of treatment 
with fluphenazine (open bars), olanzapine (light gray bars), risperido-
ne (closed bars), or quetiapine (dark gray bars) in war veterans with 
psychotic combat-related posttraumatic stress disorder. P<0.001 for 
each treatment group before vs after treatment (Tukey’s test).
Figure 7. Positive and Negative Syndrome Scale negative scores 
(mean ± standard deviation) before and after 6 weeks of treatment 
with fluphenazine (open bars), olanzapine (light gray bars), risperido-
ne (closed bars), or quetiapine (dark gray bars) in war veterans with 
psychotic combat-related posttraumatic stress disorder P<0.001 for 
each treatment group before vs after treatment. *P<0.001 vs the sco-
res after 6 weeks of treatment with risperidone, olanzapine or quetia-
pine (Tukey’s test).
Figure 8. Positive and Negative Syndrome Scale general psychopa-
thology scores (mean ± standard deviation) before and after 6 weeks 
of treatment with fluphenazine (open bars), olanzapine (light gray 
bars), risperidone (closed bars), or quetiapine (dark gray bars) in war 
veterans with psychotic combat-related posttraumatic stress disorder. 
P<0.001 for each treatment group before vs after treatment. *P<0.001 
vs the scores after 6 weeks of treatment with risperidone, olanzapine 
or quetiapine (Tukey’s test).
Figure 9. Positive and Negative Syndrome Scale supplementary 
items scores (mean ± standard deviation) before and after 6 weeks of 
treatment with fluphenazine (open bars), olanzapine (light gray bars), 
risperidone (closed bars), or quetiapine (dark gray bars) in war ve-
terans with psychotic combat-related posttraumatic stress disorder. 
P<0.001 for each treatment group before vs after treatment. *P<0.001 
vs the scores after 6 weeks of treatment with risperidone or olanza-
pine (Tukey’s test).
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er decrease of 35% in the baseline Positive and 
Negative Syndrome scale scores in war veterans 
with psychotic PTSD (Figure 5). Positive scores 
were comparably decreased after all antipsychot-
ic treatment (Figure 6),whereas negative (Figure 
7) and general psychopathology (Figure 8) scores 
were decreased substantially more after olanzap-
ine, risperidone or quetiapine than after fluphen-
azine treatment. Supplementary items scores on 
the Positive and Negative Syndrome scale were 
equivalently decreased from the baseline values: 
by 65% after olanzapine or by 61% risperidone 
treatment. The reduction by 49% achieved after 
fluphenazine treatment was not significantly dif-
ferent from the decrease from baseline scores by 
57% induced by quetiapine treatment (Figure 9).
The scores in Clinical Global Impression of 
Severity of Illness scale were significantly reduced 
by 30% and 38% from the baseline scores with 
fluphenazine and quetiapine treatment, respec-
tively, and by 62% and 64% after olanzapine or 
risperidone treatment, respectively (P<0.001 for 
all, Tukey’s test).
Drug-induced Extrapyramidal Symptoms 
Scale scores and Patient’s Global Impression of 
Improvement scores significantly differed be-
tween fluphenazine-treated veterans and those 
treated with other atypical antipsychotic medica-
tions (P<0.001 Tukey’s test). War veterans with 
psychotic PTSD treated with fluphenazine had 
more extrapyramidal side effects (akathisia, rigor, 
and mild agitation), and patients had the impres-
sion of the smaller improvement than those treat-
ed with olanzapine, risperidone, or quetiapine.
Discussion
We analyzed retrospectively the effects of four 
antipsychotic drugs – fluphenazine, olanzapine, 
risperidone, and quetiapine – from 3 open-la-
bel clinical trials (25,26,41), in a well-character-
ized large group of ethnically and racially uni-
form Caucasian male war veterans, matched for 
age, combat experience, social, and cultural back-
ground, with combat-related PTSD with psy-
chotic features. All antipsychotic drugs signifi-
cantly reduced PTSD and psychotic symptoms 
in treatment-resistant war veterans with combat-
related psychotic PTSD, which is in accordance 
with previous findings (12,14,17,18,25,26,41). 
Although all patients improved significantly af-
ter antipsychotic treatment, fluphenazine, olan-
zapine, risperidone, and quetiapine differently af-
fected particular PTSD and psychotic symptoms. 
Treatment with fluphenazine, olanzapine, risper-
idone, or quetiapine equivalently and significant-
ly reduced most of the trauma re-experiencing 
symptoms, as well as positive psychotic symp-
toms of the Positive and Negative Syndrome 
Scale in treatment-resistant patients. On the oth-
er hand, clear differences were found in the ef-
fects of fluphenazine, olanzapine, risperidone, 
and quetiapine on the total PTSD symptom 
scores and total Positive and Negative Syndrome 
Scale scores, on the symptoms listed in avoidance 
and hyperarousal subscales, and in negative, gen-
eral psychopathology, and supplementary items 
subscales. Treatment with olanzapine and risper-
idone decreased total PTSD symptoms, symp-
toms of avoidance, hyperarousal, and reduced 
anger and affective lability, listed in the Positive 
and Negative Syndrome Scale supplementary 
items. This reduction of the symptoms was sig-
nificantly greater than the reduction induced by 
fluphenazine or quetiapine. The treatment with 
olanzapine, risperidone or quetiapine greatly re-
duced the total Positive and Negative Syndrome 
Scale scores and negative and general psychopa-
thology symptoms. These psychotic symptoms 
were also reduced by fluphenazine treatment, but 
its effect was weaker. Since a clinical response in 
PTSD is achieved when Clinician-administered 
PTSD Scale scores drop by 30% compared with 
baseline scores (5), all drugs used in this study 
showed good therapeutic efficacy, and patients 
had a good therapeutic response.
The clinical trials with antipsychotics in 
PTSD deserve considerable attention, since a 
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modest or significant clinical improvement was 
reported after treatment with neuroleptics or 
atypical antipsychotics in PTSD (5,14) either in 
a series of case reports (22,42-46) or in civilian 
PTSD subjects (22,42,43,47). However, the ef-
fects of antipsychotic drugs are confounded since 
participants received antipsychotic medication as 
an adjunct therapy (27,44,48-51).
The neuroleptic drug fluphenazine signifi-
cantly reduced psychotic and PTSD symptoms 
in our war veterans, as reported previously (25), 
but induced akathisia, rigor, or mild agitation, 
which were alleviated after treatment with biperi-
done. Our results are in agreement with previous 
studies that showed the thioridazine-induced 
significant improvement of the sleep disturbanc-
es and reduction of nightmares, flashbacks, and 
anxiety in patients with PTSD (52) or combat-
related PTSD (53). However, our results did 
not show the lack of improvement in the effects 
of neuroleptics compared with non-neuroleptic 
drugs in the large groups of male combat-related 
PTSD patients at baseline and after 12 months 
(54), or the failure to improve the symptoms of 
PTSD (22).
The treatment with atypical antipsychotic 
drugs in PTSD includes the use of risperidone 
(26,44-49,51), olanzapine (25,27,42,43,55,56), 
or quetiapine (41,50,57-60). Our present and 
previous results have shown that all three atypi-
cal antipsychotics induced substantial clinical 
improvement in treatment-resistant war veter-
ans with psychotic PTSD (25,26,41). The good 
efficacy of olanzapine has been confirmed by the 
clinical improvement or the reductions in the 
Clinician-administered PTSD Scale or Positive 
and Negative Syndrome Scale scores after 5-16 
weeks of treatment, either given as a monother-
apy (25,56) or as an adjunct to other existing 
medications, mainly antidepressants (27). In line 
with our data, the beneficial effects of quetiap-
ine (41,50,57-59,61) or risperidone (26,44-
49,51,60) in the treatment of PTSD were de-
scribed. The clinical improvement induced by 
the treatment with risperidone in psychotic com-
bat-related PTSD (26) was confirmed also by a 
double-blind study (49) and by a series of case re-
ports (46,51). However, only a few studies used 
risperidone as monotherapy and verified clinical 
improvement in combat-related PTSD (26,51). 
Risperidone induced akathisia, psychomotor agi-
tation, and rigor, and these side effects were alle-
viated with biperidone. Other minor side effects 
were sedation, anxiety, slightly increased appe-
tite, and weight gain of up to 4 kg. The positive 
effects of quetiapine in the treatment of PTSD 
were described in a few case reports (57,62) and 
studies (50,58,59); however, these studies most-
ly added quetiapine to an existing medication 
(50,58). The effect of quetiapine on the core 
PTSD symptoms was weaker than the effects of 
olanzapine and risperidone, but the dose used 
was lower than the one usually administered in 
schizophrenia (63). War veterans in our study 
were severely ill patients, with psychotic combat-
related PTSD, and our results are in line with the 
previous report showing that monotherapy with 
quetiapine significantly improved clinical symp-
toms of PTSD and psychosis in PTSD patients 
refractory to other treatments (41). Quetiapine 
induced only mild and transient sedation, which 
occurred during the first 2 weeks of treatment.
The common pharmacological strategy in the 
treatment of PTSD is to start with selective se-
rotonin reuptake inhibitors (13,64), alone or in 
combination with benzodiazepines, mood sta-
bilizers (65), including anticonvulsants (66), if 
necessary. However, atypical antipsychotic drugs 
(25-27,41-51,55-61) may be the drugs of choice 
in treatment-resistant combat-related PTSD 
with psychotic symptoms (8,9,11,14,17,20-26, 
29,67). Our results showed that atypical anti-
psychotic drugs (olanzapine, risperidone or que-
tiapine) had good efficacy in the treatment of 
chronic combat-related psychotic PTSD. These 
beneficial effects agree with their reported effi-
cacy in the treatment of refractory subgroups of 
schizophrenic patients (63,68) and other non-
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psychotic patients, such as treatment-resistant 
depression (69), borderline personality disorder 
(70), or severe childhood conduct disorder and 
autism (71,72).
The limitations of this study are its open and 
retrospective design and the fact that the rat-
ers, therapists, and patients were not blind to the 
treatment they received. Its value lays in the well-
characterized large group of ethnically and racially 
uniform male war veterans, matched for age, com-
bat experience, social and cultural background, 
the fact that patients received a monotherapy, 
the comparison of four antipsychotic drugs in the 
treatment-resistant combat-related PTSD with 
psychotic features, and the fact that patients were 
treated in the same facility and by the same team, 
so the treatment factors were similar.
In conclusion, our study has confirmed that 
monotherapy with atypical antipsychotics has 
clear beneficial effects in the treatment of treat-
ment-refractory war veterans with psychotic 
PTSD. These data corroborate the wide spec-
trum of efficacy of atypical antipsychotic drugs 
(69) and confirm the hypothesis that atypical an-
tipsychotics may act on the common underlying 
pathologic mechanism that may contribute to 
“treatment resistance” across diagnostic groups 
and symptom domains (48,69). Psychotic symp-
toms commonly occur in combat-related PTSD 
and the use of antipsychotic medications seems 
to offer another approach to treat psychotic sub-
type of combat-related PTSD resistant to previ-
ous antidepressant treatment.
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